Back to search

Article

Chemogenetic ligands for translational neurotheranostics

2018-12-07

Abstract excerpt

Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) are a popular chemogenetic technology for manipulation of neuronal activity in uninstrumented awake animals with potential for precision medicine-based clinical theranostics. DREADD ligands developed to date are not appropriate for such translational applications. The prototypical DREADD agonist clozapine N-oxide (CNO) lacks brain entry and conve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bf3cda34-16af-58e8-ae8d-7f8af386cc07
DOI
10.1101/487637
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Chemogenetic ligands for translational neurotheranosticsDOI 10.1101/487637
Thousandfold Cell-Specific Pharmacology of NeurotransmissionSemantic proximity
DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.Semantic proximity
Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats.Semantic proximity
New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).Semantic proximity
iPSC-derived neurons as a tool for probing molecular pharmacology of antipsychotic actionSemantic proximity
Off-target-free chemogenetic platform that decodes physiological roles of target GPCRsSemantic proximity
A suite of engineered mice for interrogating psychedelic drug actionsSemantic proximity
Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.Semantic proximity
Positron Emission Tomography (PET) Imaging Tracers for Serotonin ReceptorsSemantic proximity
DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue.Semantic proximity
Discovery of Heterocyclic Nonacetamide Synaptic Vesicle Protein 2A (SV2A) Ligands with Single‐Digit Nanomolar Potency: Opening Avenues towards the First SV2A Positron Emission Tomography (PET) LigandsSemantic proximity
Clemastine fumarate repurposing in neuropharmacology: bibliometric mapping of pharmacological evolution, remyelination research, and translational challengesSemantic proximity
Select a neighboring publication to make it the new centre.